A COMPLETE PRODUCT containing both a Toxoid and Cell Associated Antigens.
DOUBLE ADJUVANTED with LIFE^¨II
MULTIPLE ISOLATES of P. haemolytica are used
REDUCES MORTALITY
REDUCES LUNG LESIONS
A SAFE PRODUCT -- FIELD EVALUATED
FREE FLOWING FOR EASE IN ADMINISTRATION

A case study on the flexibility of Leukotox..

Leukotox is a newly formulated bacterin-toxoid utilizing advanced technology for Pasteurella haemolytica.

Leukotox uses a combination of immunostimulators consisting of oil, water and other potentiators to drive the immune system. The product was designed to be used with re-vaccination 2-3 weeks apart so that the animals would have the maximum effect from the bacterin.

However, in the real world of raising cattle, vaccination schedules on labels are not always followed. Therefore, the following question always comes up, "If I do not give the second vaccination on time, do I still get benefit from the first vaccination when I re-vaccinate?" Or, "If I re-vaccinate 60-90 days later are the animals protected after the second does?" In short, "Is the vaccine flexible?"

To provide data on this subject, mixed-bred beef calves were vaccinated at 60-90 days of age and re-vaccinated 120 days later. Two products were utilized in the study. The first product was a monovalent Pasteurella haemolytica Bacterin-Toxoid. The second product contained Haemophilus somnus, P. multocida, Salmonella dublin-typhimurium in addition to P. haemolytica Bacterin-Toxoid.

The calves remained on the ranch of origin during the 120 day period. A 120 day interval was chosen to fit the outside extreme. This was suggested by a practitioner since the 120 day period is about the maximum time frame that would be encountered.

Two weeks following the second vaccination the animals were challenged using the transthoracic route to inject a virulent Pasteurella haemolytica challenge culture direct into the lungs. Both lungs were injected. Four days later the lungs were examined and the lesions measured. The results are presented in the table below.

Group	Animal #	Lung		Total Area (CM3)
		Left	Right
	27	5.5 x 5.0 x 4.0 = 110	5.5 x 4.5 x 7.0 = 173.25	283.25
	30	5.0 x 3.5 x 3.5 = 61.25	5.0 x 3.0 x 4.5 = 67.5	128.75
	33	6.5 x 5.7 x 6.0 = 222.3	9.5 x 5.0 x 8.0 = 380	602.3
	47	10.0 x 6.0 x 5.75 = 345	6.0 x 4.0 x 3.5 = 84	429.0
	50	4.5 x 5.0 x 5.5 = 123.75	10.5 x 8.0 x 9.0 = 756	879.75
	Average Size of Lung Lesions			464.61
	29	2.5 x 3.0 x 3.5 = 26.25	2.0 x 3.0 x 4.0 = 24	50.25
	26	2.0 x 2.0 x 1.0 = 2	3.0 x 2.75 x 3.5 = 28.9	30.9
	49	0.75 x 2.0 x 1.5 = 2.25	Too small to measure	2.25
	25	2.75 x 1.0 x 2.0 = 5.5	5.0 x 5.0 x 4.5 = 112.5	118.0
	31	3.0 x 2.5 x 3.0 = 22.5	5.0 x 4.0 x 4.0 = 80	102.5
	Average Size of Lung Lesions			60.78

*Five animals were vaccinated and challenged with both the monovalent and the combination products. Only five vaccinates were necropsied since the lesion sizes in the vaccinates were so small.